Company intelligence / Profile preview

Artoss

St. Cloud, Minnesota, United Statesnanobone.us ↗

Ownership: Private
Development stage: Commercial

Overview

Artoss commercializes advanced bone graft substitute products based on its proprietary NanoBone technology, which combines nanocrystalline hydroxyapatite with a silica gel matrix. These products are used clinically for orthopedic and dental applications to promote natural bone regeneration. The company has established itself as an innovator in synthetic bone grafts, with clinical use supporting efficacy for various indications.

Therapeutic areas: Other
Modalities: DeviceHydrogel-based drug delivery therapy
Industry: Surgical Medical Devices

Drug pipeline

1 asset

NanoBone

Commercial

Indications: Bone regeneration, Orthopedic trauma, Spinal fusion, Dental reconstruction

Beyond the preview

Go deeper on Artoss.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Artoss.

Explore the full profile